Entrepreneur
Why microplastics in intimate care demand a scientific response

Dr Olivia Ahn, founder of FLUUS
The FemTech industry is rapidly innovating, but the conversation often neglects a fundamental issue: material safety.
While we focus on digital tracking and advanced fabrics, the tiny, ubiquitous fragments of plastic in our personal care products, microplastics, pose a significant, yet often silent, threat to women’s intimate and systemic health.
As a former doctor who moved into material science, my research focuses on the intersection of these two fields, particularly exploring the pathways through which microplastics from period and intimate care products enter the bloodstream.
The current evidence demands a radical shift in how founders and manufacturers approach product design.
The Ubiquity of the Problem
Microplastics, defined as plastic particles smaller than five millimeters, are no longer confined to remote oceans or deep-sea trenches.
Recent studies have demonstrated their presence in every part of the human body, including the bloodstream, lungs, placenta, and reproductive tissues.
For the FemTech and consumer health sectors, this raises profound questions. While we often focus on microplastics shed from synthetic clothing or food packaging, we must address direct exposure pathways.
Many single-use period pads and liners contain synthetic polymers, adhesives, and backsheets, which are all sources of microplastic shedding through friction and degradation.
Even when the outer layer is organic cotton, the hidden core materials can present a systemic risk.
The Intimate Absorption Pathway: A “Fast Track” to the Bloodstream
The primary concern with microplastics in intimate care lies in the unique vulnerability of the vaginal and vulval mucosa.
Unlike the skin on our arm, which is designed to be a tough, protective barrier (keratinized epithelium), the vaginal mucosa is highly specialised and much more permeable. It is a richly vascularised tissue meaning it contains a high concentration of tiny blood vessels just beneath the surface.
This structure allows for:
1. Rapid Systemic Uptake
The tissue acts almost like a sponge, allowing substances to be absorbed quickly and directly into the circulatory system. In medicine, this pathway is leveraged for rapid drug delivery, confirming its efficiency.
2. Bypassing First-Pass Metabolism
When substances are absorbed through the gut, they pass through the liver, which acts as a primary filter to detoxify or metabolize compounds.
When chemicals or microplastics enter via the vaginal mucosa, they can bypass this critical “first-pass” mechanism, potentially leading to higher systemic exposure levels of the contaminants.
When microplastics are present in a period pad, making prolonged, intimate contact with the mucosa, there is a clear and high-risk pathway for these particles to cross the tissue barrier and enter the bloodstream.
The Broader Implications for Women’s Health
The health impact of microplastics is complex and still emerging, but existing evidence raises serious red flags, particularly for gynaecological and reproductive health:
Inflammation and Oxidative Stress:
Microplastics are known to induce inflammation and oxidative stress in cell cultures and animal models.
Chronic, low-grade inflammation is a foundational mechanism for numerous diseases, including endometriosis, Polycystic Ovary Syndrome (PCOS), and cardiovascular issues.
Microplastics has not been linked to be causative to these conditions, but reducing any source of inflammatory burden is critical for overall health.
Hormonal Disruption:

Dr Olivia Ahn
Microplastics can act as carriers, or “Trojan horses,” for endocrine-disrupting chemicals like phthalates and BPA, which are added during plastic manufacturing.
When the microplastic enters the body, it releases this cocktail of EDCs, which mimic or interfere with natural hormones.
This disruption is directly linked to fertility challenges, impaired ovarian function, and altered reproductive development.
Reproductive Tissue Accumulation:
Recent studies are particularly alarming, detecting microplastics in human ovary follicular fluid, semen, and the placenta.
These findings suggest that microplastics are accumulating in the very tissues responsible for reproduction and fetal development, demanding immediate action to minimise exposure.
Setting a New Standard for Integrity
The challenge for founders and manufacturers is no longer merely to sell a product, but to assume full responsibility for its material science and its entire lifecycle.
We must move past the industry’s status quo where products are chemically complex and built to last centuries.
We must advocate for radical transparency in ingredient disclosure and invest in genuine, circular technology that eliminates these pollutants at the source.
The next generation of femtech must prioritise both the user’s health and the planet’s health equally
The Fluus Standard: Zero Microplastics, Zero Waster and Zero Compromise
This drive for scientific integrity is the foundation of Fluus.
We developed our proprietary Flushtec technology to prove that a 100 per cent microplastic-free, fully flushable period pad is not just an ideal, but a reality.
By eliminating plastic SAPs and traditional hot-melt acrylic adhesives, we deliver genuine confidence, ensuring the product fully disintegrates after use, leaving zero waste and zero microplastic residue behind.
News
Sun Pharma to acquire Organon in US$11bn deal
News
Women’s digital health market set to reach US$5.28 billion in 2026 – report
Entrepreneur
Future Fertility raises Series A financing to scale AI tools redefining fertility care worldwide

Future Fertility Inc. has announced the closing of a US$4.1 million Series A financing round.
The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners, with participation from new investors Sandpiper Ventures, Gaingels, and Jolt VC.
The financing will accelerate Future Fertility’s commercial expansion into Asia-Pacific and support its entry into the United States, including planned FDA 510(k) clearance for additional products as part of a broader U.S. market entry strategy.
Proceeds will also advance the development of a broader AI platform, from egg assessment through to embryo transfer, designed to support clinicians, embryologists, and patients across the full IVF journey.
M Ventures and Whitecap have supported Future Fertility’s mission to translate AI innovation into meaningful clinical outcomes since the company’s earliest stages.
Oliver Hardick, investment director, M Ventures, said: “Future Fertility is addressing a critical unmet need in reproductive medicine with a differentiated AI platform grounded in clinical data and real-world workflow integration.
“We are excited to continue supporting the company and team because we believe its technology has the potential to improve decision-making for clinicians, bring greater clarity to patients, and help advance a more personalised standard of care in fertility treatment.”
Future Fertility’s AI platform addresses a long-standing gap in fertility care: historically, there has been no objective, clinically validated method for assessing egg quality (Gardner et al., 2025), despite it being one of the most important drivers of reproductive success.
The company’s suite of deep learning tools includes VIOLET™, MAGENTA™, and ROSE™, purpose-built for egg freezing, IVF, and egg donation respectively.
The tools are based on AI models trained and validated on more than 650,000 oocyte images and are deployed in over 300 clinics across 35 countries.
Rhiannon Davies, founding and managing partner, Sandpiper Ventures, said: “The best outcomes in fertility care globally come from better data and smarter tools. Future Fertility understands that, and they’ve built a platform that delivers on it.
“Sandpiper is proud to back a team turning rigorous science into real results for patients and clinicians alike.”
Partnerships with the world’s leading fertility networks – including IVI RMA and Eugin Group across Latin America and Europe, FertGroup Medicina Reproductiva in Brazil, and most recently announced Kato Ladies Clinic in Japan – reflect growing demand for objective, AI-powered oocyte assessment in fertility care. In the United States, ROSE™ is newly available under an FDA 513(g) determination.
Research shows that approximately 50 per cent of IVF patients do not understand their likelihood of success, and many discontinue treatment prematurely, even though cumulative success rates improve significantly with multiple cycles (McMahon et al., 2024).
By delivering earlier clarity on egg quality, Future Fertility’s tools support more informed conversations between clinicians and patients, helping set realistic expectations and guide decisions about next steps.
Future Fertility’s growing evidence base spans seven peer-reviewed publications in Human Reproduction, Reproductive BioMedicine Online, Fertility & Sterility, and Nature’s Scientific Reports, and more than 70 scientific abstracts accepted and presented with partner clinics at conferences worldwide.
Christine Prada, CEO, Future Fertility, said: “Fertility treatment is one of the most emotionally and physically demanding experiences a person can go through.
“Every patient deserves objective data, not just a best guess, to support better decisions at critical moments in their care.
“This funding means we can bring that clarity to more patients, in more countries, at a moment when it matters most.”
Find out more about Future Fertility at futurefertility.com
Entrepreneur4 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
News3 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Diagnosis4 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Pregnancy4 weeks agoNIPT or NT scan? Why the 2026 evidence supports doing Both
Wellness4 weeks agoResistance training has preventative effects in menopause, study finds
Mental health4 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
Insight3 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Wellness3 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
















